BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

SEQUOIA

More Like This

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BeiGene Reports First Quarter 2024 Financial Results and Business Updates